Original Article Levofloxacin and Gentamicin Induced Nephrotoxicity Pak Armed Forces Med J 2015; 65(4): ORIGINAL ARTICLES

Size: px
Start display at page:

Download "Original Article Levofloxacin and Gentamicin Induced Nephrotoxicity Pak Armed Forces Med J 2015; 65(4): ORIGINAL ARTICLES"

Transcription

1 Original Article Levofloxacin and Gentamicin Induced Nephrotoxicity Pak Armed Forces Med J 2015; 65(4): DETERMINATION OF THE EFFECTS OF LEVOFLOXACIN ON GENTAMICIN INDUCED NEPHROTOXICITY IN RABBITS: A COMPARATIVE STUDY Uzma Naeem, Shahid Jamal, Akbar Waheed Army Medical College, National University of Sciences and Technology Islamabad, Pakistan ABSTRACT Objective: To determine the effects of levofloxacin on gentamicin induced nephrotoxicity in rabbits. Study Design: Comparative experimental study. ORIGINAL ARTICLES Place and Duration of Study: The animal house of Army Medical College, Rawalpindi, and the pathology department of Army Medical College, Rawalpindi, from July 2009 to January Material and Methods: The effects of levofloxacin on gentamicin-induced nephrotoxicity were evaluated in rabbits. Twenty four rabbits were used in this study which were randomly divided into four groups (n= 6 in each group). Six animals were injected for 15 days with saline (NaCl; 0.9%), six with gentamicin alone at doses of 20 mg/kg of body weight/12 h (intramuscularly), six with combination of gentamicin (20 mg/kg/12 h) with low therapeutic doses of levofloxacin (30 mg/kg/24 h) and the last six were treated with gentamicin and high therapeutic doses of levofloxacin (50 mg/kg/24 h). Levofloxacin was given by intraperitoneal route. Results: Gentamicin induced nephrotoxicity was evaluated by histopathological and serum analysis. The extent of nephrotoxicity was significantly increased when gentamicin was given in combination with levofloxacin both in low and high doses. Conclusion: Levofloxacin enhances gentamicin induced nephrotoxicity and extent of this nephrotoxicity increased with increasing dose of levofloxacin. Keywords: Gentamicin, Histopathology, Levofloxacin, Nephrotoxicity, Serum analysis. INTRODUCTION Kidney is the target organ for numerous environmental toxins and therapeutic agents like antibiotics 1. One of the most important side affects of antibiotics is acute or chronic renal failure. Wide range of toxicity has been reported with commonly rates of 5-14% for nephrotoxicity 2. Although aminoglycosides are being used for the treatment of several gram negative bacterial infections, but consumption of large quantities may cause nephrotoxicity. Gentamicin is probably one of the most commonly used aminoglycosides for the treatment of gram negative infections 3. Like all other aminoglycosides, gentamicin is essentially eliminated by glomerular filtration. Gentamicin gets accumulated in proximal tubules and leads to the production of free radicals in these Correspondence: Dr Uzma Naeed, House No. 04, Main Street, Salah ud din Avenue, Link Airport Road, Rawalpindi, Pakistan uzmanaem88@gmail.com Received: 12 Jul 2010; revised received 29 Apr 2015; accepted 30 Apr 2015 tubules 4. However the pathological mechanisms involved in gentamicin induced nephrotoxicity include induction of oxidative stress, apoptosis, necrosis, up regulation of transforming growth factor B (TGF-B), elevation of endothelin1 and increase in monocyte/macrophage infiltration 5. Levofloxacin is a synthetic broad spectrum antimicrobial belonging to the class of fluoroquinolones. Levofloxacin has an extended spectrum of activity compared with oldergeneration fluoroquinolones (ciprofloxacin, ofloxacin), with improved activity against gram-positive bacteria and excellent activity against gram-negative bacteria and atypical organisms 6. It is primarily excreted by the kidneys. The effects on kidney that have been reported rarely with levofloxacin include mild interstitial nephritis, occult blood in urine, decreased urine function and crystallurea 7. Levofloxacin has proven efficacy against Pseudomonas aeruginosa infections and is also in use in combination with gentamicin for treatment of pseudomonal infections 7. As levofloxacin and gentamicin are used synergistically, it is imperative that effects of 439

2 levofloxacin on gentamicin induced nephrotoxicity should be evaluated. MATERIAL AND METHODS This study was a comparative experimental study which was carried out in the animal house of Army Medical College and analysis was done in the pathology department of Army Medical College Rawalpindi. Duration of study was six months. Gentamicin preparations commercialized for clinical applications were used for the current study 8. Injection gentamicin (containing 80 mg of gentamicin sulfate in 2ml solution) prepared by Reckette and Colman Pharmaceuticals, Karachi, Pakistan were purchased from local market. Pure salt of levofloxacin was generously donated by Amson Pharmaceuticals, Rawalpindi, Pakistan. From this salt solutions were prepared for intraperitoneal injections. All 36 animals were divided randomly into four groups, with six rabbits in each. Gentamicin was administered intramuscularly 9, whereas levofloxacin was administered by intraperitoneal route 16. Gentamicin was given at twelve hour interval at 8 a.m and at 8 p.m 8 while levofloxacin was given at 24 hour interval 17 for a period of fourteen days according to the following regimen: Group 1 (G-1) served as control and received 0.5 ml of isotonic saline twice daily 8. Group 2 (G-2) received gentamicin sulfate Table: Renal functions of the rabbits on serum analysis. TESTS G-1 G1 G-2 G-2 G-3 G-3 G-4 G-4 BUN mmol/l ±0.82 ±0.7 ±0.56 ± 0.52 ±0.3 ± 0.81 ±0.84 ± p<0.001 p<0.001 p<0.001 S. Creatinine µmol/l ±6 ±5.65 ±6.72 ± ±4.51 ± ±6.10 ± p<0.01 p<0.01 p<0.001 S. Sodium mmol/l ±1.86 ± 1.07 ±1.75 ± 3.98 ±2.06 ± 1.68 ±1.09 ± 3.71 p= NS p = NS p<0.04 S. Potassium mmol/l ±0.17 ± 0.15 ±0.3 ± 0.31 ±0.17 ± 0.23 ±0.2 ± 0.35 p = NS p = NS p<0.04 S. Calcium mmol/l ±0.05 ± 0.07 ±0.07 ± 0.21 ±0.1 ± 0.5 ±0.05 ± 0.11 p = NS p = NS p = NS 40mg/kg/day, nephrotoxic dose 10. Group 3 (G-3) received combination of gentamicin 40 mg/kg/day and levofloxacin 30 mg/kg/day 11. Group 4 (G-4) received gentamicin 40 mg/kg/day and levofloxacin 50 mg/kg/day 12. Blood was collected twice during the study period from the marginal ear veins. First samples were taken at the start of study and second after 15 days. The collected blood was allowed to clot at room temperature and then centrifuged at 3000 rpm for 15 minutes. Serum was separated with the help of an automatic micropipette and stored in a clean and dry serum storage vial at C for estimation of 440

3 Levofloxacin and Gentamicin Induced Nephrotoxicity urea, creatinine and electrolytes potassium and calcium) later on. (sodium, Pak Armed Forces Med J 2015; 65(4): RESULTS After 15 days of treatment, a significant difference was observed between the groups. Gentamicin given for 15 days at 40 mg/kg/day All the animals were sacrificed 24 hours after the last dose of the drug8. The abdomen was opened by a longitudinal incision immediately after death. Both the kidneys were dissected out and removed after cutting the ureters and renal vessels. Capsules were stripped off gently. Kidney specimens were sliced sagitally and placed in 10% formaline for 24 hours. The kidney tissue then processed for paraffin embedding. Approximately 3-5µm thick sections were taken with a rotary microtome. Sections were mounted on glass slides and stained with Hematoxylin and Eosin stain (H. & E. stain) for routine histopathological study under light microscope with special attention to proximal tubules. Figure-1: Microscopic structures of rabbit renal cortex of animals treated with gentamicin showing tubular necrosis (X400). Serum creatinine and BUN levels were measured by automated enzymatic assays. Serum creatinine was measured by Jaffe reaction13 and BUN levels by urease kinetic method14. Serum sodium and potassium were measured by ion selective electrode method and serum calcium by CPC method. Histopathological abnormalities were scored on plastic sections at X400 magnification. Each slide was coded. Sections were taken from three different regions of renal cortex for each rabbit. The lesions in renal cortex were scored: 0= No cell necrosis, 1= Mild, only single cell necrosis in sparse tubules, 2= Moderate, more than one cell involved in sparse tubules, 3= Marked, tubules exhibiting total necrosis in almost every power field, 4= Massive total necrosis15. Figure-2: left; Microscopic structures of proximal tubules of the rabbits treated with combination of gentamicin and levofloxacin (low doses) showing necrosis, inflammatory infiltrate and flattening and desquamation of tubular cells (X400). Right; Microscopic structures of proximal tubules of rabbit kidneys treated with gentamicin and high doses of levofloxacin showing inflammatory cells and lost tubular as well as cellular pattern (X400). The standard error of means was calculated on computer using Microsoft Office Excel In order to find the significance of the difference between two observations Student s t test was used. The difference between two observations was considered significant if the p value was less than The results of histopathology were analyzed by using the Chi Square Test. The difference between the two observations was considered significant if the p value was less than induced a significant change in serum creatinine levels and BUN compared with control animals, their p values were and 0.01 respectively. Concomitant administration of levofloxacin with gentamicin both in low and high doses significantly raised serum creatinine and BUN levels, although both parameters were still significantly higher in the rabbits receiving combination of gentamicin and high doses of levofloxacin (p < for both parameters). 441

4 Serum sodium, potassium and calcium levels were statistically almost unchanged in animals treated with gentamicin alone and with gentamicin-levofloxacin (low doses) combination on day 15. But a significant change in serum sodium (p < 0.04) and serum potassium levels (p < 0.01) was observed in animals treated with combination of gentamicin and high doses of levofloxacin as compared with control. Data is shown in the table. After 15 days of treatment with gentamicin alone, renal proximal tubular cells showed patchy necrosis, grade 2 necrosis (figure-1). While treatment with gentamicin plus low doses of levofloxacin resulted in slightly increased focal necrosis of proximal tubules but overall assessment was also that of grade 2 (figure 2 left). In this group infiltration of interstitium with different inflammatory cells including some eosinophils (showing type ш hypersensitivity reaction) was also observed, particularly in the surroundings of necrotic tubules. As the dose of levofloxacin was increased element of necrosis and inflammatory component both were augmented, but the tubular necrosis was still in grade 2 with more marked inflammatory infiltration of interstitium (figure-2 right). By applying chi square test p value was not significant. DISCUSSION This study strongly suggests that levofloxacin enhances the gentamicin-induced nephrotoxicity. This assumption is based on various criteria such as the rise in serum creatinine and BUN levels and more severe histopathological lesions in the renal cortex of the animals treated with gentamicinlevofloxacin combination (although p value is insignificant) compared with the animals treated with gentamicin alone. Levofloxacin is one of the safest and best tolerated fluoroquinolone over a wide range of daily doses 16. It is not primarily nephrotoxic, but it has nephrotoxic potential especially in old age and in immuno compromised patients 17. Our present work was based upon the hypothesis that fleroxacin, a fluoroquinolone can attenuate gentamicin induced nephrotoxicity in rats 8. Protection against aminoglycoside induced nephrotoxicity has been demonstrated for many antibiotics or chemical compounds. Actually, several antimicrobials including ceftriaxone, ticarcillin, carbenicillin, latamoxef and daptomycin 18,19, decrease gentamicin induced nephrotoxicity. This protection occurs with or without a reduction in the uptake of gentamicin, suggesting different mechanisms of protection. Even though such combinations of gentamicin and levofloxacin are not additive or synergistic in vitro 8, they are often used clinically, like the combination of gentamicin and antipseudomonal fluoroquinolones (ciprofloxacin and levofloxacin) in the treatment of Pseudomonas aeruginosa infections 20. Besides gentamicin persists within the renal parenchyma for many months after their use, and since they are often used as step down therapy following intravenous therapy, the chances of exposing the kidneys to these combinations are high. CONCLUSION It can be concluded from present work that caution must be exercised when using gentamicin with levofloxacin due to enhancement of nephrotoxic potential. It is also concluded that nephrotoxic potential enhances with increasing the dose of levofloxacin. CONFLICT OF INTEREST This study has no conflict of interest to declare by any author. Acknowledgement: The authors acknowledge the assistance of Mr Mukarram Shah, Lab Tech Histopathology, for preparing histopathology slides. REFERENCES 1. Solhauq MJ, Bolqer PM, Jose PA. The developing kidney and environmental toxins. Pediatrics 2004; 113(4): Baykal A, Sarigul F, Suleymanlar G, Moreira PI, Perry G, Smith MA, et al. Ciprofloxacin does not exert nephrotoxicity in rats. Am J Infec Dis 2005; 1(3) : Martinez-Salqado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 2007; 223(1): Abdel-Raheem IT, Abdel-Ghany AA, Mohammad GA. Protective effects of quercetin against gentamicin induced nephrotoxicity in rats. Boil Pharm Bull 2009; 32(1): Balakumar P, Rohilla A, Thangathirupathi A. gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it. Pharmacol Res 2010; 62(3): Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinoloneresistant Campylobactera species and the withdrawal of 442

5 fluoroquinolones from use in poultry. A public health success story. Clin Infect Dis 2007; 44 (7): Patterson DR. Quinolones toxicity: methods of evaluation. Am J Med 1991; 91(6A): Beauchamp D, Laurent G, Grenier L, Gourde P, Zanen J, Bergeron MG. Attenuation of aminoglycoside induced nephrotoxicity in rats by fleroxacin. Antimicrobe Agents Chemother 1997; 41(6): Aziz B, Mustafa KB, Nusret A, Mehmet NO. Effect of sevoflurane anesthesia on the severity of renal histopathologic changes in rabbits pretreated with gentamicin: A controlled, investigator-blinded, experimental study. Curr Ther Research 2006; 67(6): Yasin KF, Sabir M, Sherwani MK, Zafar M, Yasmin S, Alam MI. Amelioration of gentamicin induced nephrotoxicity by vitamin B6 (a general and histochemical profile). Pakistan J Med Res 2003; 42(2). 11. Shirtliff ME, Calhoun JH, Mader T. Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin- susceptible Staphylococcus aureus osteomyelitis in rabbits. J Antimicrob Chemother 2001; 48(2): Murillo O, Domenech A, Garcia A, Tubau F, Cabellos C, Gudiol F, et al. Efficacy of high doses levofloxacin in experimental foreign body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50(12): Young DS. Effects of disease on clinical lab. Tests. 4th ed 2001; AACC. 14. Burtis CA, Ashwood ER. Tietz textbook of clinical chemistry. 3rd. W.B Saunder Company 1991; Derakhshanfar A, Bidadkosh A, Sadeghian M. L-methionine attenuates gentamicin-induced nephrotoxicity in male wister rats: pathological and biochemical finding. Iranian J Vet Res 2009; 10(4): Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clinical cornerstone, Monograph 2004; Hung CC, Kuo MC, Chang JM, Chen HC. Fluoroquinolone-induced acute interstitial nephritis in immunocompromised patients: two case reports. Nephrol Dial Transplant 2006; 21(1): Beauchamp D, Theriault G, Grenier L, Gourde P, Perron S, Bergeron Y, et al. Ceftriaxone protects against tobramycin nephrotoxicity. Antimicrob Agents Chemother 1994; 38: English J, Gilbert DN, Koelhepp S, Koehnen PW, Mayor G, Houghton DC, et al. Attenuation of an experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother 1985; 27: Mandell LA, Wunderink RG, Anzueto RG. Infectious diseases society of America. American thoracic society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 2007; 44(2): S

Patients. Excludes paediatrics, neonates.

Patients. Excludes paediatrics, neonates. Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All

More information

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient 1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime

More information

Intravenous Antibiotic Therapy Information Leaflet

Intravenous Antibiotic Therapy Information Leaflet Scottish Adult Cystic Fibrosis Service Ninewells Hospital Dundee Intravenous Antibiotic Therapy Information Leaflet February 2008 Intravenous antibiotic therapy in cystic fibrosis Patients with cystic

More information

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017 Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell

More information

Persistent in Kidneys

Persistent in Kidneys ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1981, p. 381-385 0066-4804/81/030381-05$02.00/0 Vol. 19, No. 3 Prevention of Acute and Chronic Ascending Pyelonephritis in Rats by Aminoglycoside Antibiotics

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND

More information

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer

More information

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin

More information

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0

More information

Introduction to Pharmacokinetics and Pharmacodynamics

Introduction to Pharmacokinetics and Pharmacodynamics Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats

Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats THE JOURNAL OF INFECTIOUS DISEASES VOL. 124, SUPPLEMENT DECEMBER 1971 1971 by the University of Chicago. All rights reserved. Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats J. Allan Wait,

More information

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Dose-Dependent Amelioration of Gentamicin-Induced Nephrotoxicity in Adult Swiss Albino Rats by Vitamin B-complex - A Preliminary Study

Dose-Dependent Amelioration of Gentamicin-Induced Nephrotoxicity in Adult Swiss Albino Rats by Vitamin B-complex - A Preliminary Study Tropical Journal of Pharmaceutical Research, April 2009; 8 (2): 111-116 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Research Article

More information

Pharmacological Evaluation of Amikacin in Neonates

Pharmacological Evaluation of Amikacin in Neonates ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.

More information

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008 Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin

More information

ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE

ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE Version 1.0 Date ratified June 2009 Review date June 2011 Ratified by Authors Consultation Nottingham Antibiotic Guidelines Committee

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nuzyra) Reference Number: CP.PMN.## Effective Date: 11.20.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Coding Implications Revision Log See Important Reminder

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS

ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS Contents 1. How to I calculate a gentamicin dose?... 2 2. How do I prescribe gentamicin on the cardex?... 2 3. Can I give

More information

Speciality: Therapeutics

Speciality: Therapeutics Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which

More information

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS

More information

EPAR type II variation for Metacam

EPAR type II variation for Metacam 23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents

More information

Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization

Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization

More information

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. BOEHRINGER INGELHEIM VETMEDICA, INC. USA Product Label http://www.vetdepot.com 2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506 2002 Telephone: 800 325 9167 Fax: 816 236 2717 Email: www.bi vetmedica.com

More information

Appropriate Antimicrobial Therapy for Treatment of

Appropriate Antimicrobial Therapy for Treatment of Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul

More information

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health

More information

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS 390 CHEMOTHERAPY JULY 1967 GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS M. OHOKOSHI*, Y. NAIDE, T. KAWAMURA, K. SUZUKI,

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials Clinical Monitoring of Outpatient Parenteral Antimicrobial Therapy (OPAT) and Selected Oral Antimicrobial Agents Adult Inpatient/Ambulatory Clinical Practice Guideline Appendix A. Coordinating an OPAT

More information

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017. Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care

Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Jennifer McCann, PharmD, BCCCP State Director of Clinical Pharmacy Services St. Vincent Health Indiana Conflicts of Interest No

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:

More information

Pharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed

Pharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation

More information

Considerations in antimicrobial prescribing Perspective: drug resistance

Considerations in antimicrobial prescribing Perspective: drug resistance Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active

More information

Effectiveness and Toxicity of Gentamicin in an Experimental Model of Pyelonephritis: Effect of the Time of Administration

Effectiveness and Toxicity of Gentamicin in an Experimental Model of Pyelonephritis: Effect of the Time of Administration ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1999, p. 1020 1026 Vol. 43, No. 5 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Effectiveness and Toxicity of

More information

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes

More information

moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering

moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:

More information

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

European Public MRL assessment report (EPMAR)

European Public MRL assessment report (EPMAR) 18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

CF WELL Pharmacology: Microbiology & Antibiotics

CF WELL Pharmacology: Microbiology & Antibiotics CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure

More information

DOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)

DOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline

More information

Single-Dose Toxicity Study in Beagle or Mixed Breed Dogs. MTD Determination with Repeat Dose Range-Finding in Beagle or Mixed Breed Dogs

Single-Dose Toxicity Study in Beagle or Mixed Breed Dogs. MTD Determination with Repeat Dose Range-Finding in Beagle or Mixed Breed Dogs Single-Dose Toxicity Study in Beagle or Mixed Breed Dogs MTD Determination with Repeat Dose Range-Finding in Beagle or Mixed Breed Dogs 14- Day Repeat Toxicity Study in Beagle or Mixed Breed Dogs Single-Dose

More information

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES:

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES: CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug

More information

Anesthesia Check-off Form

Anesthesia Check-off Form Anesthesia Check-off Form 5231 SW 91st Drive Gainesville, FL 32608 (352) 377-6003 The doctors and staff at Haile Plantation Animal Clinic would like to offer the most advanced medical care and services

More information

Diabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals

Diabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals Diabetic Foot Infection Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals History of previous amputation [odds ratio (OR)=19.9, P=.01], Peripheral vascular disease (OR=5.5, P=.007)

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each ml contains: Tilmicosin 300 mg;

More information

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient

More information

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.

More information

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox

More information

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10999/033/001A Case No: 7006569 The in exercise of the powers conferred on it by Animal Remedies

More information

Staphylex Flucloxacillin (sodium)

Staphylex Flucloxacillin (sodium) Staphylex Flucloxacillin (sodium) PRODUCT INFORMATION Name of the Medicine Flucloxacillin sodium is the sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate. Structural

More information

Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle

Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Treatment Study DRAXXIN vs. Nuflor July 2005 Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Pfizer Animal Health, New York,

More information

International Journal for Pharmaceutical Research Scholars (IJPRS)

International Journal for Pharmaceutical Research Scholars (IJPRS) International Journal for Pharmaceutical Research Scholars (IJPRS) V-3, I-2, 2014 ISSN No: 2277-7873 CASE STUDY Acute Kidney Injury Following Antibiotic Spacer Placement for Two-Stage Arthroplasty Gregory

More information

Jerome J Schentag, Pharm D

Jerome J Schentag, Pharm D Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE

More information

Indian Journal of Canine Practice Volume 6 Issue 2, December, 2014

Indian Journal of Canine Practice Volume 6 Issue 2, December, 2014 THERAPEUTIC TRIALS OF PYODERMA IN DOGS WITH CLINDAMYCIN AND IN COMBINATION WITH A TOPICAL ANTIBACTERIAL COMBINATION OF CHLORHEXIDINE GLUCONATE AND SILVER SULPHADIAZENE M.A. Kshama¹ and S.Yathiraj² ¹Assistant

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle

More information

Period of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)

Period of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit) Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's

More information

CLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:

CLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met: CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur... SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.

More information

Central Nervous System Infections

Central Nervous System Infections Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY

More information

Isolation, identification and antimicrobial susceptibility pattern of uropathogens isolated at a tertiary care centre

Isolation, identification and antimicrobial susceptibility pattern of uropathogens isolated at a tertiary care centre International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 10 (2015) pp. 951-955 http://www.ijcmas.com Original Research Article Isolation, identification and antimicrobial

More information

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets

Active Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 500 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 500 mg cephalexin

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including

More information

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1 Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director

More information

* gender factor (male=1, female=0.85)

* gender factor (male=1, female=0.85) Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12

More information

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Pharmacology Week 6 ANTIMICROBIAL AGENTS Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe

More information

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets

Active Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 1000 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 1000 mg cephalexin

More information

PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION

PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION Read all of this leaflet carefully before you start taking this

More information

folate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole

folate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole Folate Antagonists Enzymes requiring folate-derived cofactors are essential for the synthesis of purines and pyrimidines (precursors of RNA and DNA) and other compounds necessary for cellular growth and

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Kelacyl 100 mg/ml, solution for injection for cattle and pigs (BG, CY, CZ, DE, EL, FR, HU, IE, IT, LT, PL, PT, RO, SK, UK)

More information

Final Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014

Final Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality

More information

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America

More information

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption. A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE CARTON BOX AND LABELS OF 100 ml and 250 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT TILKOMAY 300 mg/ml + 90 mg/ml solution

More information